Sugino Hitomi, Kitamura Mayu, Yoshioka Manabu, Saito-Sasaki Natsuko, Sawada Yu
Dermatology, Kyushu Rosai Hospital, Kitakyushu, JPN.
Dermatology, University of Occupational and Environmental Health, Kitakyushu, JPN.
Cureus. 2024 Nov 12;16(11):e73530. doi: 10.7759/cureus.73530. eCollection 2024 Nov.
Pembrolizumab is a PD-1 inhibitor that has improved survival in melanoma patients but can cause immune-related adverse events (irAEs) such as hypothyroidism and uveitis. Although these conditions rarely occur together, we present a case of a 54-year-old female with plantar malignant melanoma who developed hypothyroidism after the second cycle of pembrolizumab and then uveitis after the fifth cycle. Hypothyroidism was treated with levothyroxine, and uveitis was managed with corticosteroids. This case highlights the importance of careful monitoring and multidisciplinary management of these adverse events during immunotherapy.
帕博利珠单抗是一种PD - 1抑制剂，它提高了黑色素瘤患者的生存率，但可引起免疫相关不良事件（irAEs），如甲状腺功能减退和葡萄膜炎。虽然这些情况很少同时发生，但我们报告了一例54岁的足底恶性黑色素瘤女性患者，在接受帕博利珠单抗第二个周期治疗后出现甲状腺功能减退，在第五个周期后出现葡萄膜炎。甲状腺功能减退用左甲状腺素治疗，葡萄膜炎用皮质类固醇治疗。该病例强调了在免疫治疗期间对这些不良事件进行仔细监测和多学科管理的重要性。
